戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ent of patients with newly diagnosed primary CNS lymphoma.
2 l nervous system (CNS) and is called primary CNS lymphoma.
3 mosis medications alone, and one patient had CNS lymphoma.
4  23% had TP53 mutation, and 8% had secondary CNS lymphoma.
5 plantation (HSCT) in patients with secondary CNS lymphoma.
6 SCT in patients with newly diagnosed primary CNS lymphoma.
7 ell transplantation in patients with primary CNS lymphoma.
8 ssessment, staging, and treatment of primary CNS lymphoma.
9 ines for immunocompetent adults with primary CNS lymphoma.
10 ation, and tissue biopsy in the diagnosis of CNS lymphoma.
11 ore than 95% specificity in the diagnosis of CNS lymphoma.
12 aseline risk evaluation in untreated primary CNS lymphoma.
13 6.1% in human immunodeficiency virus-related CNS lymphoma.
14 le and active in the treatment of refractory CNS lymphoma.
15 )F-FDG PET as a prognostic marker in primary CNS lymphoma.
16 resurgical evaluation for cases of suspected CNS lymphoma.
17 iotherapy (rdWBRT) and cytarabine in primary CNS lymphoma.
18 le and active in the treatment of refractory CNS lymphoma.
19 tients aged 70 years or younger with primary CNS lymphoma.
20 t may contribute to the pathogenesis of this CNS lymphoma.
21  role for JCV in the pathogenesis of primary CNS lymphoma.
22  brain metastasis, and primary and secondary CNS lymphomas.
23 fractory embryonal brain tumours and primary CNS lymphomas.
24 s-positive control tissues including several CNS lymphomas.
25 atistically significant (P = 0.011) in these CNS lymphomas.
26 mor vasculature as well as by tumor cells in CNS lymphomas.
27 ling, by tumor cells and tumor endothelia in CNS lymphomas.
28 recurrent/refractory central nervous system (CNS) lymphoma.
29 specimens of primary central nervous system (CNS) lymphomas (12/27 [44.4%]), an EBV-associated malign
30 -5.2%]; BL, 21.5% [95% CI, 17.7%-25.4%]; and CNS lymphoma, 12.9% [95% CI, 10.5%-15.3%]; all P < .001
31 10.5%]; BL, 27.8% [95% CI, 25.0%-30.5%]; and CNS lymphoma, 48.3% [95% CI, 46.7%-49.8%]; all P < .001
32 mors include primary central nervous system (CNS) lymphoma (7%) and malignant forms of ependymomas (3
33 onsisted of 26 multiple sclerosis, 8 primary CNS lymphoma, 84 aquaporin-4 immunoglobulin G positive,
34 isruption is known to occur in patients with CNS lymphoma, a direct link between these two has not be
35                          Patients with known CNS lymphoma, active hepatitis B or C infection, or HIV
36                          The pathogenesis of CNS lymphomas affects multiple compartments within the n
37 udy in patients with newly diagnosed primary CNS lymphoma (age 18-60 years).
38 ed 18-70 years) with newly diagnosed primary CNS lymphoma and an Eastern Cooperative Oncology Group p
39  up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomi
40 gates of prognosis and treatment response in CNS lymphoma and brain metastasis.
41 and identify several hundred CSF proteins in CNS lymphoma and control patients.
42 ged 18-65 years with newly diagnosed primary CNS lymphoma and immunocompetence, with no limitation on
43 ed 18-70 years) with newly diagnosed primary CNS lymphoma and measurable disease were enrolled from 5
44 c method for rapid differential diagnosis of CNS lymphoma and toxoplasmosis in patients with AIDS.
45 ith high doses of antimetabolites in primary CNS lymphoma and with rituximab plus high-dose sequentia
46 e elucidation of the molecular properties of CNS lymphomas and their microenvironment, as well as evo
47 rent knowledge regarding the pathogenesis of CNS lymphomas and to highlight promising strategies that
48 diagnosis of primary central nervous system (CNS) lymphoma and cerebral toxoplasmosis in patients wit
49 terleukin (IL)-10 in central nervous system (CNS) lymphomas and to evaluate the utility of each as pr
50 t lymphoma [BL], and central nervous system [CNS] lymphoma), and cervical cancer.
51 cell lymphoma, Burkitt lymphoma, and primary CNS lymphoma, and to a lesser extent, Hodgkin lymphoma.
52 tients age 18 to 70 years old with secondary CNS lymphoma, and we propose it as a new standard therap
53 ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selective
54 rends of CNS malignancies, including primary CNS lymphomas, and on survival probability.
55    Patients with multiple sclerosis, primary CNS lymphoma, aquaporin-4 immunoglobulin G positivity, n
56 , such as glioblastoma multiforme or primary CNS lymphomas, are less common.
57 ial addressing a new treatment for secondary CNS lymphoma based on encouraging experiences with high
58  young patients with newly diagnosed primary CNS lymphoma, but further comparative studies are needed
59 e-based chemotherapy is standard for primary CNS lymphoma, but most patients relapse.
60                      Central nervous system (CNS) lymphoma can present a diagnostic challenge.
61 cases, 27.1% (95% CI, 26.1%-28.1%) of 27,265 CNS lymphoma cases, and 0.42% (95% CI, 0.37%-0.47%) of 3
62 s [immunoblastic and central nervous system (CNS) lymphoma] caused by loss of T-cell function, and (2
63                  In vitro treatment of BAL17(CNS) lymphoma cells by AMD3100, which inhibits CXCR4-CXC
64 xate (HD-MTX) and rituximab in patients with CNS lymphoma (CNSL).
65 IAN in patients with central nervous system (CNS) lymphoma (CNSL) treated with CD19-directed chimeric
66           Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet
67 is and other neurological syndromes and with CNS lymphomas (CNSLs).
68                                    Recurrent CNS lymphoma continues to be associated with poor outcom
69 trexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of ind
70   We conducted a review of the literature on CNS lymphoma diagnosis (1966 to October 2011) to determi
71                                   Although a CNS lymphoma diagnosis was once assumed to be uniformly
72 sis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
73 retention index is useful in differentiating CNS lymphomas from other malignant and nonmalignant path
74 can help distinguish central nervous system (CNS) lymphoma from toxoplasmosis and other nonmalignant
75 s and their contribution to the diagnosis of CNS lymphoma in 91 diffuse large B-cell lymphomas (DLBCL
76 ymptoms in DLBCL and BL and with parenchymal CNS lymphoma in DLBCL; sCD19 emerged as a powerful predi
77 n normal, thus explaining the propensity for CNS lymphomas in AIDS.
78                         Treatment of primary CNS lymphoma includes high-dose methotrexate-containing
79                                 When primary CNS lymphoma initially involves the retina, it is named
80                                    Secondary CNS lymphoma is a rare but potentially lethal event in p
81                                      Primary CNS lymphoma is an aggressive form of non-Hodgkin lympho
82                    The management of primary CNS lymphoma is one of the most controversial topics in
83              Primary central nervous system (CNS) lymphoma is an aggressive non-Hodgkin lymphoma with
84                      Central nervous system (CNS) lymphoma is an extranodal non-Hodgkin B-cell lympho
85              Primary central nervous system (CNS) lymphoma is an unusual but increasingly frequent br
86 s, their efficacy in central nervous system (CNS) lymphoma is unknown.
87 e chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.
88  show that while individual cases of primary CNS lymphomas may be classified as germinal center B-cel
89  scale, or MILAS) was used to assess primary CNS lymphoma metabolism as a marker of clinical aggressi
90          We also identify high expression in CNS lymphomas of several IL-4-induced genes, including X
91 n the neuroaxis, and proper treatment of the CNS lymphoma patient requires a multidisciplinary team w
92  concentration of CXCL13 and IL-10 in CSF of CNS lymphoma patients and control cohorts including infl
93 nogen around B-cell lymphoma was detected in CNS lymphoma patients and in the CNS parenchyma in an or
94 ur institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlec
95 ssibly a cure, for a significant fraction of CNS lymphoma patients.
96  AIDS subjects, including those with primary CNS lymphoma (PCNSL) (outside the area of neoplastic inv
97                                      Primary CNS lymphoma (PCNSL) and primary intraocular lymphoma (I
98 valuation and response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparabilit
99                                      Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B
100 rs for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive
101                                      Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Ho
102                                      Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clini
103                                      Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumo
104                              PURPOSE Primary CNS lymphoma (PCNSL) is confined to the CNS and/or the e
105 viously reported on 31 patients with primary CNS lymphoma (PCNSL) treated between 1986 and 1992 with
106         Four patients with recurrent primary CNS lymphoma (PCNSL) were studied.
107                                      Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non
108 ontrol and survival in patients with primary CNS lymphoma (PCNSL).
109 ation therapy (RT) for patients with primary CNS lymphoma (PCNSL).
110 patients with relapsed or refractory primary CNS lymphoma (PCNSL).
111 eutic strategies as consolidation in primary CNS lymphoma (PCNSL).
112 d initial high-dose methotrexate for primary CNS lymphoma (PCNSL).
113              Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (P
114 rare form of primary central nervous system (CNS) lymphoma (PCNSL) arising in the intraocular compart
115              Primary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma
116 atients with primary central nervous system (CNS) lymphoma (PCNSL) were excluded from all pivotal CAR
117 rimary and secondary central nervous system (CNS) lymphoma poses a unique set of diagnostic, prognost
118 aventricular rituximab/MTX, including 1 with CNS lymphoma refractory to high-dose systemic and intrat
119  Optimum treatment for patients with primary CNS lymphoma remains challenging because there have not
120 Standard treatment for patients with primary CNS lymphoma remains to be defined.
121 (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature.
122            Secondary central nervous system (CNS) lymphoma (SCNSL) is a rare but clinically challengi
123 IL-10 as potentially important biomarkers of CNS lymphoma that merit further evaluation and support i
124 at intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-lik
125 any Radiation Therapy Oncology Group primary CNS lymphoma trial.
126  in newly diagnosed non-AIDS-related primary CNS lymphoma was conducted in the New Approaches to Brai
127 petent patients with newly diagnosed primary CNS lymphoma who underwent pretreatment (18)F-FDG PET we
128  an independent set of patients with primary CNS lymphoma who were treated with high-dose intravenous
129 t modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that
130  study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and
131 r PET represents a novel diagnostic tool for CNS lymphoma with potential implications for theranostic
132 are the gene expression signature of primary CNS lymphomas with nodal large B-cell lymphomas.
133 was 99.3% specific for primary and secondary CNS lymphoma, with sensitivity significantly greater tha

 
Page Top